The important developments related to the use of BCL-2 and IDH inhibitors in leukemia treatment could represent only the first step in the introduction into cancer therapeutics of drugs targeting the apoptotic machinery, with future developments possibly involving other members of the BCL-2 family and members of the TRAIL-family. This evidence concerns the gene BCL2 and cancer.